Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Administration JMKX003142 in Chinese Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Single, and Multiple Ascending Dose Phase I Clinical Trial.
Saved in:
| Title: | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Administration JMKX003142 in Chinese Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Single, and Multiple Ascending Dose Phase I Clinical Trial. |
|---|---|
| Authors: | Cui C; Drug Clinical Trial Center, Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, People's Republic of China.; Center of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, People's Republic of China.; Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, Peking University Third Hospital, Beijing, 100191, People's Republic of China., Zhu J; Drug Clinical Trial Center, Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, People's Republic of China.; Center of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, People's Republic of China., Liu Z; Drug Clinical Trial Center, Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, People's Republic of China.; Center of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, People's Republic of China.; Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, Peking University Third Hospital, Beijing, 100191, People's Republic of China., Liu J; Drug Clinical Trial Center, Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, People's Republic of China.; Center of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, People's Republic of China., Huang X; Drug Clinical Trial Center, Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, People's Republic of China.; Center of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, People's Republic of China., Liu Y; Clinical Development Center, Shanghai Jeyou Pharmaceutical Co.,Ltd., Shanghai, 200120, People's Republic of China., Hu J; Clinical Development Center, Shanghai Jeyou Pharmaceutical Co.,Ltd., Shanghai, 200120, People's Republic of China., Zhang L; Clinical Development Center, Shanghai Jeyou Pharmaceutical Co.,Ltd., Shanghai, 200120, People's Republic of China., Zhang X; Clinical Development Center, Shanghai Jeyou Pharmaceutical Co.,Ltd., Shanghai, 200120, People's Republic of China., Sha Y; Clinical Development Center, Shanghai Jeyou Pharmaceutical Co.,Ltd., Shanghai, 200120, People's Republic of China., Liu D; Drug Clinical Trial Center, Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, People's Republic of China.; Center of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, People's Republic of China.; Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, Peking University Third Hospital, Beijing, 100191, People's Republic of China., Li H; Drug Clinical Trial Center, Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, People's Republic of China.; Center of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, People's Republic of China.; Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, Peking University Third Hospital, Beijing, 100191, People's Republic of China. |
| Source: | Drug design, development and therapy [Drug Des Devel Ther] 2026 Mar 05; Vol. 20, pp. 583445. Date of Electronic Publication: 2026 Mar 05 (Print Publication: 2026). |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I |
| Journal Info: | Publisher: Dove Press Limited Country of Publication: New Zealand NLM ID: 101475745 Publication Model: eCollection Cited Medium: Internet ISSN: 1177-8881 (Electronic) Linking ISSN: 11778881 NLM ISO Abbreviation: Drug Des Devel Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1177-8881 |
|---|---|
| DOI: | 10.2147/DDDT.S583445 |
